MedTrace Logo

Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients

NCT05889494 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-03-18

No results posted yet for this study

Summary

The goal of this pilot trial is to test a protocol for a planned Canada-wide clinical trial looking at whether or not the use of a patients own blood works as good as the current standard of care using donated blood products to reduce blood loss in adult patients having heart surgery.

The main questions this study aims to answer are:

* Is the protocol practical, effective, and efficient.
* Does the use of a patients own blood lower the following: bleeding, the amount donated blood products given, and complications.

Participants will be separated into two groups by a process that is like flipping a coin. One group will donate blood to themselves in the operating room and get their own blood back after surgery. The other group will be given blood products donated by other humans to treat the bleeding after heart surgery.

Researchers will compare both groups to see if patients that get their own blood have fewer donated blood products given at time of heart surgery and have less complications after surgery.

Conditions

  • Postoperative Hemorrhage
  • Postoperative Anemia
  • Postoperative Blood Loss

Interventions

OTHER

Autologous Whole Blood Management

Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.

OTHER

Standard Care involving allogenic and/or derivative transfusion.

Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.

Sponsors & Collaborators

  • University Hospital Foundation

    collaborator OTHER

  • Alberta Innovates Health Solutions

    collaborator OTHER

  • EPICORE Centre

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Angela R Neufeld, MD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2026-01-27
Completion
2026-02-26

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889494 on ClinicalTrials.gov